BiotechTube

R744 + Epoetin beta

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Predialysis Patients

Conditions

Predialysis Patients

Trial Timeline

Jun 1, 2007 → Nov 1, 2008

NCT ID
NCT00492427

About R744 + Epoetin beta

R744 + Epoetin beta is a phase 3 stage product being developed by Chugai Pharmaceutical for Predialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00492427. Target conditions include Predialysis Patients.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00492427Phase 3Completed

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
EmicizumabPhase 3
77
Divarasib + Sotorasib + AdagrasibPhase 3
77